Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Romark’s Investigational Covid-19 Drug Lowers Disease Progression in Trial
Details : NT-300 is an oral, broad-spectrum antiviral drug designed to provide antiviral concentrations of drug to the respiratory tract throughout twice-daily dosing.
Brand Name : NT-300
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2021
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Romark Initiates New Phase 3 Clinical Trial Of NT-300 For The Treatment Of COVID-19
Details : The Phase 3 clinical trial aims to evaluate safety and efficacy of Romark's investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19.
Brand Name : NT-300
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 11, 2020
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Romark Initiates Phase 3 Clinical Trials Of NT-300 For COVID-19
Details : Clinical development program for NT-300 includes trials addressing prevention and treatment of COVID-19 and other viral respiratory illnesses.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2020
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?